ClinicalTrials.Veeva

Menu

Effects of Beta-blockade on Platelet Aggregation in Acute Coronary Syndrome (PLATE-BLOCK)

F

Federico II University

Status and phase

Completed
Phase 4

Conditions

Acute Coronary Syndrome

Treatments

Drug: Metoprolol
Drug: Carvedilol

Study type

Interventional

Funder types

Other

Identifiers

NCT02809820
CE-9/14

Details and patient eligibility

About

The Investigators will test the hypothesis that nonselective beta-blockers would have a more pronounced effect on platelet aggregation than selective beta-blockers in patients with acute coronary syndrome treated with dual anti platelet therapy.

Full description

In patients with acute coronary syndrome (ACS) beta-blockers are recommended for secondary prevention. It is known that catecholamine levels can potentiate platelet reactivity and beta-blocking agents may also affect platelet aggregation. This effect is mainly mediated by adrenergic receptors on platelets. This suggests that nonselective beta-blockers would have a more pronounced effect on platelet aggregation than selective beta-blockers. However, little is known about the effect of beta-blockers on platelet aggregation in patients with cardiovascular disease and, to date, nothing is known in the setting of ACS.

The aim of the present study is to evaluate the effect of selective and nonselective beta-blockers on platelet aggregation in ACS patients treated with dual anti platelet therapy.

Enrollment

100 patients

Sex

All

Ages

18 to 99 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Acute Coronary Syndrome
  • Current dual anti platelet treatment with acetylsalicylic acid and Ticagrelor

Exclusion criteria

  • ongoing prasugrel, ticlopidine or clopidogrel therapy
  • Creatinine Clearance < 30 ml/min/1.73mm2
  • Moderate to severe anemia Hemoglobin < 10 mg/dl
  • Platelet count >600000/mm3 or <150000/mm3 or hematocrit >50% or <25%
  • concomitant neoplastic or immune-mediated pathologies
  • severe pulmonary pathologies
  • contraindication to beta blocker therapy.

Trial design

Primary purpose

Basic Science

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

100 participants in 2 patient groups

Carvedilol
Active Comparator group
Description:
Patients who have documented ACS, who are on dual antiplatelet therapy and are randomized to assume carvedilol.
Treatment:
Drug: Carvedilol
Metoprolol
Active Comparator group
Description:
Patients who have documented ACS, who are on dual antiplatelet therapy and are randomized to assume metoprolol.
Treatment:
Drug: Metoprolol

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems